Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.76)
# 780
Out of 4,761 analysts
141
Total ratings
54.78%
Success rate
44.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $11.07 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $19.90 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $700.33 | +21.37% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.12 | +1,507.14% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $3.10 | +1,835.48% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $4.29 | +109.79% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $5.68 | +498.59% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $140.64 | +132.51% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $3.94 | +661.42% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $71 | $1.25 | +5,580.00% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $484.24 | -41.97% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.80 | +344.44% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.42 | +6,801.41% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $303.01 | -2.64% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $109.95 | -21.78% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $30.88 | +55.44% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.66 | +157.29% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $35.22 | +104.43% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.54 | +224.68% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $72.11 | +38.68% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $152.43 | +31.86% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $50.69 | +67.69% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $7.93 | +303.53% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $106.28 | +104.18% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $18.59 | +158.20% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $16.37 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $250.59 | -38.55% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $68.25 | +69.96% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $2.91 | +3,548.88% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $12.17 | +130.07% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $191.21 | -57.12% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $361.10 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.65 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.07
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.90
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $700.33
Upside: +21.37%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.12
Upside: +1,507.14%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $3.10
Upside: +1,835.48%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $4.29
Upside: +109.79%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $5.68
Upside: +498.59%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $140.64
Upside: +132.51%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $3.94
Upside: +661.42%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $1.25
Upside: +5,580.00%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $484.24
Upside: -41.97%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.80
Upside: +344.44%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.42
Upside: +6,801.41%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $303.01
Upside: -2.64%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $109.95
Upside: -21.78%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $30.88
Upside: +55.44%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $11.66
Upside: +157.29%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $35.22
Upside: +104.43%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.54
Upside: +224.68%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $72.11
Upside: +38.68%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $152.43
Upside: +31.86%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $50.69
Upside: +67.69%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $7.93
Upside: +303.53%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $106.28
Upside: +104.18%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $18.59
Upside: +158.20%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $16.37
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $250.59
Upside: -38.55%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $68.25
Upside: +69.96%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $2.91
Upside: +3,548.88%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $12.17
Upside: +130.07%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $191.21
Upside: -57.12%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $361.10
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.65
Upside: -